UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation UGN-301 formulated in a reverse thermal gel allowed sustained exposure in the bladder Some patients receiving UGN-301 (zalifrelimab) intravesical solution showed clinical activity at the week 12 disease assessment Data presented at the 2025 American Urological Association … [Read more…]

CORRECTING and REPLACING EyeCare Partners Presents Latest Innovations in Eye Care at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 in Los Angeles

ST. LOUIS–(BUSINESS WIRE)–Please replace the release dated April 23, 2025, with the following corrected version due to multiple revisions. The updated release reads: EYECARE PARTNERS PRESENTS LATEST INNOVATIONS IN EYE CARE AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS) 2025 IN LOS ANGELES EyeCare Partners (ECP), the nation’s leading provider of clinically integrated … [Read more…]

Herbalife Welcomes Lynda Cloud to its Board of Directors

LOS ANGELES–(BUSINESS WIRE)–Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the election of Lynda Cloud to its Board of Directors, effective April 23, 2025. This appointment reflects Herbalife’s continued commitment to innovation, digital transformation, and personalized wellness. Lynda Cloud’s decades of leadership across education, technology, and health sectors … [Read more…]

Kardium Announces 1-Year PULSAR IDE Study Results for Its PFA Device – the Globe® PF System

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed field ablation (PFA) device—the Globe PF System. These pivotal findings from the PULSAR IDE study were announced at the Heart Rhythm Society (HRS) meeting in … [Read more…]

FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients

Analysis also shows that changes in ctDNA accurately detect BRAF mutations from tumor biopsies; differentiated pattern of acquired mutations supports dimer–breaking properties of plixorafenib Company also showcases FORTE basket study design with a Trials in Progress poster PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, … [Read more…]

30% of All US Medical Visits to Be Conducted via Telemedicine by 2026, ScienceSoft Predicts

MCKINNEY, Texas–(BUSINESS WIRE)–ScienceSoft released proprietary research exploring the adoption of telemedicine in the United States. Relying on statistical insights, first-hand opinions from healthcare industry representatives, and market data, the report estimates that, by the end of 2026, around 30% of all medical appointments in the United States will be conducted via telemedicine technologies. The research … [Read more…]

Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

Advancements include CosMx® 2.0 upgrade; CosMx same-slide multiomics; and multiomics capabilities on the nCounter® platform CHICAGO–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These new advancements build upon the innovations announced at … [Read more…]

Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows

TÜBINGEN, Germany–(BUSINESS WIRE)–With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications. Five configurations for … [Read more…]

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

– Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of influenza virus, from an infected person to household members by 32% – – CENTERSTONE is the first global phase III trial that demonstrates the benefit of an antiviral in reducing the spread of a respiratory virus … [Read more…]

LIA, Lightning Step’s AI Assistant, wins Silver Stevie® Award for 2025 Healthcare Technology Solution of the Year

HOUSTON–(BUSINESS WIRE)–#AI–Another major milestone achieved by LIA: Lightning Step is proud to announce that its AI-powered assistant has been awarded the Silver Stevie® Award for 2025 Healthcare Technology Solution of the Year. This recognition celebrates LIA’s growing impact on clinical efficiency and quality of care across behavioral health and addiction treatment centers. The Stevie® Awards … [Read more…]